Therma Bright's Venowave VW5 Secures Medicare Reimbursement Status Through HCPCS Code

Therma Bright Inc. has achieved a critical milestone in the medical technology sector with its Venowave VW5 compression therapy device receiving a permanent Healthcare Common Procedure Coding System code from the U.S. Centers for Medicare and Medicaid Services. This designation makes the Venowave VW5 the only Medicare-approved, reimbursable mobile mechanical compression system available in the United States, providing significant advantages for both patients and healthcare providers seeking effective treatment solutions.

The FDA-designated Durable Medical Equipment device offers patients a lightweight and compact alternative for managing post-operative recovery, pain, and swelling issues. The permanent HCPCS code status enables broader patient access through insurance coverage, potentially reducing out-of-pocket expenses for individuals requiring compression therapy treatments. This reimbursement approval represents a substantial market advantage for Therma Bright in the competitive medical device landscape.

Recent distribution partnerships have further strengthened the company's market position. DME Authority, a national medical device distributor, has committed to a substantial inventory purchase including an initial order of 1,750 Venowave VW5 units. This partnership represents potential HCPCS code reimbursements of approximately $1.43 million, demonstrating significant commercial interest in the technology. Another national distributor, Valor Medical, has placed an initial order for 100 units with potential for regular future purchases, indicating growing market acceptance.

The global compression therapy market presents substantial growth opportunities for Therma Bright's technology. According to Straits Research, the market was valued at $4.18 billion in 2024 and is projected to reach $6.72 billion by 2033, with a compound annual growth rate of 7.30%. This expanding market landscape provides favorable conditions for the company's continued expansion and product adoption.

Beyond the Venowave VW5, Therma Bright is developing additional innovative medical technologies that could further enhance its market position. The company is pursuing FDA classification for its acoustic AI Digital Cough Technology, a remote therapeutic monitoring solution designed to help healthcare providers and epidemiologists collect and analyze respiratory data. These strategic developments position Therma Bright as an emerging player in the medical device technology sector with potential for continued innovation in both compression therapy and remote monitoring solutions.